Leerink Partners analyst Marc Goodman reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) Inc on Tuesday, setting a price target of $115, which is approximately 101.72% above the present share price of $57.01.
Goodman expects Axsome Therapeutics Inc to post earnings per share (EPS) of $0.00 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Axsome Therapeutics, with an average price target of $135.67.
The analysts price targets range from a high of $225 to a low of $104.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$27.84 million. The company's market cap is $2.14 billion.
According to TipRanks.com, Leerink Partners analyst Marc Goodman is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.1% and a 48.19% success rate.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.